Therapeutic Advances for Huntington’s Disease
Open accessThe DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is a progressive neurological disease that is inherited in an autosomal fashion. The cause of disease pathology is an expansion of cytosine-adenine-guanine (CAG) repeats within the huntingtin gene (HTT) on chromosome 4 (4p16.3), which codes the huntingtin protein (mHTT). The common symptoms of HD include motor and cognitive impairment of psychiatric functions. Patients exhibit a representative phenotype of involuntary movement (chorea) of limbs, impaired cognition, and severe psychiatric disturbances (mood swings, depression, and personality changes). A variety of symptomatic treatments (which target glutamate and dopamine pathways, caspases, inhibition of aggregation, mitochondrial dysfunction, transcriptional dysregulation, and fetal neural transplants, etc.) are available and some are in the pipeline. Advancement in novel therapeutic approaches include targeting the mutant huntingtin (mHTT) protein and the HTT gene. New gene editing techniques will reduce the CAG repeats. More appropriate and readily tractable treatment goals, coupled with advances in analytical tools will help to assess the clinical outcomes of HD treatments. This will not only improve the quality of life and life span of HD patients, but it will also provide a beneficial role in other inherited and neurological disorders. In this review, we aim to discuss current therapeutic research approaches and their possible uses for HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–227 of 227
Management of Huntington’s disease: role of tetrabenazine
Tommaso, D. (2011) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s17152 · Cited by 40
Modulation of Mutant Huntingtin N-Terminal Cleavage and Its Effect on Aggregation and Cell Death
Juenemann, K., Weisse, C., Reichmann, D., Kaether, C., Calkhoven, C. F., & Schilling, G. (2010) · Neurotoxicity Research · doi:10.1007/s12640-010-9227-6 · Cited by 38
Bonelli, R. M., Niederwieser, G., Diez, J., Gruber, A., & Költringer, P. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200201000-00011 · Cited by 37
Pietropaolo, S., Bellocchio, L., Ruiz-Calvo, A., Cabanas, M., Du, Z., Guzmán, M., Garret, M., & Cho, Y. H. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.021 · Cited by 36
Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease
Waters, N., Tedroff, J., Pontén, H., Klamer, D., Sonesson, C., & Waters, N. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170267 · Cited by 36
da Silva, A. B. G., Naia, L., Dominguez, A., Ribeiro, M., Rodrigues, J., Vieira, O. V., Leßmann, V., & Rego, A. C. (2015) · Neurodegenerative Diseases · doi:10.1159/000375447 · Cited by 34
Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons
Ehrnhoefer, D. E., Caron, N. S., Deng, Y., Qiu, X., Tsang, M., & Hayden, M. R. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.06.008 · Cited by 34 · cited 1×
“It is recently undergoing a phase II clinical trial in human HD patients [149].”
BackgroundMoser, A. D., Epping, E. A., Espe‐Pfeifer, P., Martin, E., Zhorne, L., Mathews, K. D., Nance, M., Hudgell, D., Quarrell, O. W. J., & Nopoulos, P. (2017) · Neurodegenerative Disease Management · doi:10.2217/nmt-2017-0019 · Cited by 34 · cited 1×
“Disrupted sleep, tics, pain, itching, and psychosis are the common symptoms of juvenile HD [18].”
BackgroundThe P42 peptide and Peptide-based therapies for Huntington’s disease
Marelli, C., & Maschat, F. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0405-3 · Cited by 34 · cited 1×
“In transgenic mouse models of HD like R6/2, N171-82Q, YAC128, and BACHD, treatment with intrabody gene therapy improved body weight, motor function, cognitive, and neuropathological manifestation [66,106].”
BackgroundCoenzyme Q10 serum levels in Huntington’s disease
Andrich, J., Carsten Saft, C., Gerlach, M., Schneider, B., Arz, A., Kuhn, W., & Müller, T. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_13 · Cited by 32 · cited 1×
“Coenzyme Q10 cofactor is involved in ATP production in the electron transport chain (ETC) of mitochondria, and its supplementation in HD patients may improve mitochondrial function [89].”
BackgroundA 5-year follow-up of deep brain stimulation in Huntington's disease
López-Sendón, J. L., García‐Caldentey, J., Regidor, I., del Álamo, M., & de Yébenes, J. G. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.11.007 · Cited by 31
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
McGarry, A. J., McDermott, M., Kieburtz, K. D., et al. (2017) · Publisher · Cited by 28
Riluzole Stimulates BDNF Release from Human Platelets
Türck, P., & Frizzo, M. E. (2015) · BioMed Research International · doi:10.1155/2015/189307 · Cited by 25 · cited 2×
“Treatment with minocycline proved to be neuroprotective, and to improve the disease phenotype [30,42,44].”
BackgroundCRISPR/Cas9-Mediated Genome Editing for Huntington’s Disease
Vachey, G., & Déglon, N. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7825-0_21 · Cited by 25
Bilateral Globus Pallidus Stimulation in Westphal Variant of Huntington Disease
Cislaghi, G., Capiluppi, E., Saleh, C., Romano, L., Servello, D., Mariani, C. B., & Porta, M. (2013) · Neuromodulation Technology at the Neural Interface · doi:10.1111/ner.12098 · Cited by 25
Cognitive function in early clinical phase huntington disease after rivastigmine treatment.
Šešok, S., Bolle, N., Kobal, J., Bucik, & Db, V. (2014) · PubMed · Cited by 25
Acetyl Cholinesterase inhibitors in cognitive impairment in Huntington’s disease: A brief review
Vattakatuchery, J. J. (2013) · World Journal of Psychiatry · doi:10.5498/wjp.v3.i3.62 · Cited by 24
Pharmacological Properties of BN82451: A Novel Multitargeting Neuroprotective Agent
Chabrier, P. E., & Auguet, M. (2007) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2007.00018.x · Cited by 24 · cited 2×
“BN82451 Decreases glutamate release by blocking Na+ channels Showed efficacy in a rodent model [80,81]”
BackgroundReilmann, R., Squitieri, F., Priller, J., Carsten Saft, C., Mariotti, C., Suessmuth, S. D., Nemeth, A. H., Tabrizi, S. J., Quarrell, O. W. J., Craufurd, D., et al. (2014) · Neurology · doi:10.1212/wnl.82.10_supplement.s47.004 · Cited by 20
Amantadine: A Review of Use in Child and Adolescent Psychiatry
Hosenbocus, S., & Chahal, R. (2013) · Europe PMC (PubMed Central) · Cited by 20
Deep brain stimulation in Huntington’s disease: Assessment of potential targets
Sharma, M., & Deogaonkar, M. S. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.11.008 · Cited by 20
Gene Therapy for Huntington’s Disease Using Targeted Endonucleases
Dabrowska, M., & Olejniczak, M. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9784-8_17 · Cited by 20
Review: The fate of cell grafts for the treatment of H untington's disease: the post‐mortem evidence
Cisbani, G., & Cicchetti, F. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12104 · Cited by 18
Tian, J., Yan, Y., Zhou, R., Lou, H., Ye, R., & Zhang, B. (2013) · Neuroscience Bulletin · doi:10.1007/s12264-013-1393-0 · Cited by 16
Sandhir, R., Mahajan, N., Mehrotra, A., Aggarwal, A., & Sunkaria, A. (2015) · Synapse · doi:10.1002/syn.21793 · Cited by 15
Reilmann, R., Squitieri, F., Priller, J., Carsten Saft, C., Mariotti, C., Süßmuth, S. D., Nemeth, A. H., Tabrizi, S. J., Quarrell, O. W. J., Craufurd, D., et al. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309032.294 · Cited by 14
Revisiting the Lamotrigine-Mediated Effect on Hippocampal GABAergic Transmission
Huang, Y., Liu, Y., Lee, C.-T., Lin, Y.-C., Wang, M., Yang, Y.-P., Chang, K.-Y., & Chiou, S. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071191 · Cited by 14 · cited 1×
“Lamotrigine is an antiepileptic drug and decreases glutamate release by blocking voltage-gated sodium channels [143,144].”
Background
Cited by
Eid, R., Arab, N. T. T., & Greenwood, M. T. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2016.12.002 · Cited by 288
Huntington disease: A single-gene degenerative disorder of the striatum
Nopoulos, P. C. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/pnopoulos · Cited by 161
Genistein induces degradation of mutant huntingtin in fibroblasts from Huntington’s disease patients
Pierzynowska, K., Gaffke, L., Cyske, Z., & Węgrzyn, G. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00405-4 · Cited by 32
Effects of NAD+ in Caenorhabditis elegans Models of Neuronal Damage
Lee, Y., Jeong, H., Park, K. H., & Kim, K. W. (2020) · Biomolecules · doi:10.3390/biom10070993 · Cited by 8
Self-citation
Metadata
- Authors
- Kumar, A., Kumar, V., Singh, K., Kumar, S., Kim, Y.-S., Lee, Y.-M., & Kim, J.-J.
- Venue
- Brain Sciences
- Publisher
- MDPI AG
- Published
- 2020-01-12
- Volume
- 10
- Issue
- 1
- Pages
- 43
- ISSN
- 2076-3425 (ISSN-L)
- OpenAlex
- W3000473074
- Cited by
- 164
- References
- 227
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.